Dover has entered into a definitive settlement to accumulate Malema Engineering Corp, a US designer and manufacturer of high-precision, mission-critical flow-measurement and management instruments for the biopharmaceutical, semiconductor and industrial sectors.
Malema’s products will expand Dover’s biopharma single-use manufacturing providing, which already consists of Quattroflow pumps, CPC connectors, and em-tec flowmeters.
Based in Boca Raton, Florida, and with facilities in San Jose, California, Singapore, South Korea and India, Malema expects to generate roughly US$40 million–45 million in revenue during the full year 2022.
When the deal closes, Malema will turn into a part of the PSG enterprise unit within Dover’s Pumps & Process Solutions section.
“We see a tremendous long-term progress opportunity within the bioprocessing business driven by a strong and growing pipeline of efficient novel biologic drugs, biosimilars, protein therapies, non-COVID mRNA vaccines, as well as budding cell & gene therapies,” says PSG’s president Karl Buscher. “Additionally, the rising adoption of more efficient single-use manufacturing processes helps a sturdy outlook for our choices of single-use parts to end-customers. เกจวัดอาร์กอน consider that pairing Malema’s know-how with our current portfolio of single-use pumps for biopharma processing will significantly improve the accuracy and value proposition of our options to our clients.”
“We are methodically building out our biopharma platform by way of proactive capacity additions, new product development, and opportunistic acquisitions of highly-attractive niche part applied sciences,” said Richard Tobin, president and CEO of Dover. “Malema represents a strategic and highly-complementary flow-control and sensing technology and further strengthens our sensor portfolio with new proprietary expertise. In addition to engaging biopharma applications, we expect robust progress in the semiconductor area on the capacity enlargement and re-shoring tailwinds.”
Share